Deborah J Andrews
CIK 1325697 · Chief Financial Officer & EVP · last filed 2026-08-18
Deborah J Andrews is a Chief Financial Officer & EVP who has filed 57 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing, for STAA, was dated Aug 18, 2026. Across all open-market trades the lifetime net is −$6.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $932.4K across reported positions. 20 SEC filings were submitted jointly with Lineage Cell Therapeutics, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
STAA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MONROVIA, CA 91016
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STAA | Chief Financial Officer & EVP | 38,910 | $23.07 | $897.7K | -$6.79M | 38 | 2026-08-18 |
| LCTX | Director | 34,720 | $1.00 | $34.7K | -$56.1K | 8 | 2026-07-02 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 10,000 | — | — | $27.7K | 10 | 2018-09-13 |
Recent Filings
57 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-18 | STAA | Mixed | +2,571 | -$69.7K | EDGAR |
| 2026-08-04 | STAA | Mixed | +17,686 | -$459.9K | EDGAR |
| 2026-07-02 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2026-05-19 | STAA | Mixed | +10,067 | -$180.6K | EDGAR |
| 2026-03-16 | STAA | Grant (A) | — | $0 | EDGAR |
| 2026-02-04 | STAA | Grant (A) | — | $0 | EDGAR |
| 2025-07-02 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2025-06-26 | STAA | Grant (A) | — | $0 | EDGAR |
| 2024-07-03 | LCTX | Grant (A) | — | $0 | EDGAR |
| 2023-07-03 | LCTX | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.